$2 here we come...., page-781

I'm still holding, but the main problems with the report, and these are fairly significant, were:

1. Deterioration in generics business. Explained as a result of being the nature of generics, that you make super profits one year and this disappears fast. This says MYX portfolio is not sufficiently diversified to weather downturns like this, and also that no new product launches to make up for older items.

2. Delays with Nuvaring. See 1 above, Nuvaring should be the next new generic product that brings in the $s

3. Improvement in SPD is great, but came with a higher cost. If you recall they hired all these additional sales force. Great that the tactic is working, but the amount of additional cost was a bit unexpected and has disappointed the market.

1 & 2 are just timing, so if you continue to hold should see a good rebound. (3) isn't a huge deal to me, SPD is a smaller part of the business.